48 completed, 11 recruiting, 10 unknown, 8 active not recruiting. 31 Phase 1, 22 Phase 2, 22 Phase 3, 9 Not applicable, 8 Phase 4.
Follow Injections, Subcutaneous: new trials by email Literature Review of Injections, Subcutaneous trials Research Report on Injections, Subcutaneous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus Semaglutide 0.25 mg, Semaglutide 0.5 mg, Semaglutide 1.0 mg - Kidney Transplant Recipient | Phase 2 / Phase 3 | Not yet recruiting | University Health Network, Toronto | 37 | 2026-09-05 | 2026-09-16 |
| Phase 1 Study Involving SAB01 and Healthy Participants Subcutaneous (SC) single dose of SAB01, Intravenous (IV) infusion of SAB01, Placebo SC - Healthy Adult Participants | Phase 1 | Recruiting | Santa Ana Bio | 88 | 2026-08-31 | 2026-09-11 |
| JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg - Malignancies, Solid Malignant Tumor | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 14 | 2026-06-25 | 2026-08-11 |
| Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity Semaglutide 1.7mg subcutaneous, Placebo - Obesity/Therapy | Phase 3 | Not yet recruiting | University of Colorado, Denver | 120 | 2026-06-15 | 2026-07-02 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
| A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism Single subcutaneous injection, Multiple subcutaneous injection - Hypoparathyroidism | Phase 2 | Suspended | Peking Union Medical College Hospital | 60 | 2026-04-13 | 2026-09-28 |
| A Clinical Study to Evaluate SM17 for Atopic Dermatitis SM17 for subcutaneous injection, SM17 placebo for subcutaneous injection - Atopic Dermatitis | Phase 2 | Recruiting | SinoMab BioScience Ltd | 200 | 2026-03-31 | 2026-04-06 |
| Study of G-CSF for DOR in Patients Undergoing IVF Neupogen 300 μg subcutaneous injection, Subcutaneous injections of a saline solution - Diminished Ovarian Reserve, IVF | Phase 4 | Recruiting | Center for Human Reproduction | 140 | 2026-02-25 | 2026-10-13 |
| Medicsen Smartpatch: Safety & Performance (SOUNDD) Medicsen Smartpatch, Subcutaneous (SC) single dose - Healthy | Not applicable | Active not recruiting | Medicsensors S.L | 30 | 2026-01-20 | 2026-05-29 |
| Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers TQB2922 injection (subcutaneous injection) - Advanced Cancers | Phase 1 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 42 | 2025-12-16 | 2026-09-10 |
| A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors TQB2934 injection (subcutaneous injection) - Multiple Myeloma | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 42 | 2025-12-09 | 2025-12-11 |
| Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism Single subcutaneous injection, Multiple subcutaneous injection - Hypoparathyroidism | Phase 1 / Phase 2 | Suspended | Peking Union Medical College Hospital | 15 | 2025-11-17 | 2026-09-25 |
| Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician - Obese Diabetics, Obese Non Diabetic | Phase 3 | Completed | Zagazig University | 159 | 2025-10-18 | 2026-09-15 |
| Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies TQB2825 Injection (Subcutaneous Injection) - CD20-positive Hematological Malignancies | Phase 1 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 75 | 2025-09-01 | 2025-08-07 |
| A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors KJ015 Injection (Subcutaneous Injection) - Gastric/Gastroesophageal Junction Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Shanghai Bao Pharmaceuticals Co., Ltd. | 66 | 2025-06-24 | 2025-06-25 |
| Dupilumab Therapy for EGIDs Dupilumab - Standard Dose, subcutaneous injection - Eosinophilic Gastrointestinal Disorders (EGIDs) | Recruiting | Children's Hospital of Fudan University | 20 | 2025-01-01 | 2025-12-02 | |
| Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous), Venetoclax, Dexamethasone - Light Chain (AL) Amyloidosis | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 36 | 2024-10-15 | 2026-07-28 |
| JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy, JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy - Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 395 | 2024-07-11 | 2025-08-28 |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig - Multiple Myeloma | Phase 1 | Active not recruiting | AbbVie | 60 | 2024-06-17 | 2026-03-27 |
Showing 20 of 91. Sign in to see all of them.
Diabetes Mellitus, Type 2 (6) · Multiple Myeloma (5) · Obesity (5) · Arthritis, Rheumatoid (4) · Asthma (4) · Breast Neoplasms (4) · Osteoporosis, Postmenopausal (4) · Dermatitis, Atopic (3) · Bone Diseases, Metabolic (2) · Carcinoma, Non-Small-Cell Lung (2) · Hypoparathyroidism (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Plasma Cell (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2)
Shenzhen People's Hospital (5) · Eli Lilly and Company (4) · Array Biopharma, now a wholly owned subsidiary of Pfizer (3) · MedImmune LLC (3) · Peking Union Medical College Hospital (3) · Pfizer (3) · AstraZeneca (2) · Bristol-Myers Squibb (2) · Hoffmann-La Roche (2) · Massachusetts General Hospital (2) · Merck Sharp & Dohme LLC (2) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (2) · AbbVie (1) · Abbott (1) · Affinivax, Inc. (1)
United States (33) · China (22) · Germany (10) · Canada (9) · France (8) · United Kingdom (8) · South Korea (7) · Belgium (6) · Spain (6) · Argentina (5) · Brazil (5) · India (5) · Poland (5) · South Africa (5) · Australia (4)
Yan Qin (2) · Adolfo Allegra, MD (1) · Allison Shapiro, PhD, MPH (1) · Anders Boss (1) · Barry Skikne, M.D., FACP; FCP (SA) (1) · Bruce Ritchie, MD (1) · C C Palanivelu, MS, MCh (1)
PMID 21618201, PMID 23176889, PMID 23706713, PMID 23740226, PMID 24584926, PMID 24624979, PMID 24839031, PMID 24842985, PMID 25629740, PMID 25664404, PMID 25698370, PMID 25787057, PMID 25933031, PMID 26296092, PMID 26691396, PMID 26843086, PMID 27061887, PMID 27161178, PMID 27229685, PMID 27683610, PMID 28431485, PMID 28817190, PMID 28881389, PMID 29388288, PMID 29989515, PMID 30822800, PMID 32356465, PMID 32501595, PMID 33418053, PMID 35017197, PMID 37385724, PMID 38654416, PMID 38669354, PMID 38789924, PMID 39612802, PMID 40073831
2023 (3), 2014 (2), 2009 (1)